Anakinra, COVID-19, Cytokine Storm
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- 100
Summary
- Conditions
- COVID-19
- Cytokine Storm
- Mechanical Ventilation Complication
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study is a phase II double-blind, placebo-controlled, multicentered trial. Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigators will follow up with patients for up to 60 days.Masking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 89 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04603742
- Collaborators
- Swedish Orphan Biovitrum
- Investigators
- Principal Investigator: Iris Y Navarro-Millan, MD, MSPH Weill Medical College of Cornell University